loader image
Wednesday, October 15, 2025
84.5 F
McAllen
- Advertisement -

Use Of Anticoagulant Drug After Aortic Valve Replacement Lowers Mortality Risk

Translate to Spanish or other 102 languages!

 Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings. Image for illustration purposes
 Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings. Image for illustration purposes
- Advertisement -

By Mayo Clinic

Newswise — ROCHESTER, Minn. — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings.

The use of bioprosthetic aortic valve replacement has increased significantly during the past decade. Among its advantages is that most patients can avoid warfarin for anticoagulation treatment. Even so, research has been conflicting on whether patients would benefit from more aggressive early postoperative anticoagulation treatment.

- Advertisement -

Mayo Clinic researchers analyzed nationwide data on more than 10,000 patients who underwent bioprosthetic aortic valve replacement. Warfarin use was associated with a 32% reduction in mortality risk. Patients treated with warfarin early postoperatively also had an increased risk of major bleeding events.

“The findings support early warfarin use in appropriately selected patients, such as patients with low bleeding risk,” says Hartzell Schaff, M.D., a Mayo Clinic cardiovascular surgeon who contributed to the study. “There’s often reluctance to prescribe anticoagulant treatment early after surgery due to concerns about bleeding and uncertainty about benefits. Our research finds that the small increased hazard of bleeding (4% versus 2.3%) may be an acceptable risk given the benefits in terms of mortality risk as well as reduced risk of thromboembolism.”

The Mayo Clinic study analyzed deidentified patient data from 2007 to 2019 using OptumLabs Data Warehouse, which contains claims data of commercially insured and Medicare Advantage enrollees of all ages and races throughout the U.S.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Clears New Blood Test that Could Speed Alzheimer’s Diagnosis and Treatment

With Alzheimer’s rates climbing and diagnoses often delayed until symptoms progress, a new FDA-cleared blood test could mark a turning point in how the disease is identified and managed.

HHSC Encourages Preventive Care During Breast Cancer Awareness Month

The Texas Health and Human Services Commission is encouraging preventive care and screenings for women during Breast Cancer Awareness Month in October.

DHR Health Urology Institute Expands Expertise with Dr. Kayvon Kian

DHR Health, one of the largest physician-owned hospitals in the United States, proudly serving the Rio Grande Valley since 1997, is excited to welcome Dr. Kayvon Kiani to our esteemed team at the DHR Health Urology Institute.

AMA Highlights New Tools for Medicare’s Open Enrollment 

The American Medical Association (AMA) is reminding Medicare patients that the annual open enrollment period has several important updates to make it easier for patients to select plans that include their physicians. 
- Advertisement -
×